Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar i disorder: A double-blind, placebo-controlled, 52-week randomized withdrawal study

Journal of Clinical Psychiatry

Volumn 78, Issue 3, 2017, Pages 324-331

  Calabrese, Joseph R ^a   Sanchez, Raymond ^b   Jin, Na ^b   Amatniek, Joan ^b   Cox, Kevin ^b   Johnson, Brian ^b   Perry, Pamela ^b   Hertel, Peter ^c   Such, Pedro ^c   Salzman, Phyllis M ^b   McQuade, Robert D ^b   Nyilas, Margaretta ^b   Carson, William H ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; PLACEBO; DELAYED RELEASE FORMULATION;

ADULT; AGED; AKATHISIA; ANXIETY DISORDER; ARTICLE; ASTHMA; BIPOLAR I DISORDER; BRAIN INJURY; CAUSE OF DEATH; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV-TR; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HEART INFARCTION; HUMAN; INFORMED CONSENT; INJECTION SITE REACTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESPIRATORY FAILURE; RESTLESSNESS; RHINOPHARYNGITIS; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; AFFECT; BIPOLAR DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG SUBSTITUTION; FOLLOW UP; INTRAMUSCULAR DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PSYCHOLOGY; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AFFECT; ARIPIPRAZOLE; BIPOLAR DISORDER; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 85017022542     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.16m11201     Document Type: Article

References (48)

1. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder, second edition. APA web site. http://psychiatryonline.org/pb/assets/raw/ sitewide/practice-guidelines/guidelines/ bipolar.pdf. Accessed July 21, 2016.
2. Grunze H, Vieta E, Goodwin GM, et al; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154-219. PubMed doi:10.3109/1562975.2013.7051
3. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1-44. PubMed doi:10.1/bdi.12025
4. Bortolato B, Miskowiak KW, Köhler CA, et al. Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of metaanalyses. Neuropsychiatr Dis Treat. 2015;11:3111-3125. PubMed doi:10.2147/ndt.s7670
5. Martinez-Aran A, Scott J, Colom F, et al. Treatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry. 2009;70(7):1017-1023. PubMed doi:10.408/JCP.08m0408
6. Zimmerman M, Galione JN, Chelminski I, et al. Sustained unemployment in psychiatric outpatients with bipolar disorder: frequency and association with demographic variables and comorbid disorders. Bipolar Disord. 2010;12(7):720-726. PubMed doi:10.1/j.139-5618.2010.0869.x
7. Baune BT, Malhi GS. A review on the impact of cognitive dysfunction on social, occupational, and general functional outcomes in bipolar disorder. Bipolar Disord. 2015;17(suppl 2):41-55. PubMed doi:10.1/bdi.12341
8. López-Jaramillo C, Lopera-Vásquez J, Gallo A, et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord. 2010;12(5):557-567. PubMed doi:10.1/j.139-5618.2010.0835.x
9. Kemp DE. Managing the side effects associated with commonly used treatments for bipolar depression. J Affect Disord. 2014;169(suppl 1):S34-S44. PubMed doi:10.1016/S0165-0327(14)707-2
10. Szmulewicz A, Samamé C, Caravotta P, et al. Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications. Int J Bipolar Disord. 2016;4(1):6. PubMed doi:10.186/s40345-016-047-3
11. Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry. 2007;7:40. PubMed doi:10.186/1471-24X-7-40
12. Kanba S, Kawasaki H, Ishigooka J, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). World J Biol Psychiatry. 2014;15(2):113-121. PubMed doi:10.3109/1562975.2012.69047
13. Keck PE Jr, Calabrese JR, McIntyre RS, et al; Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007;68(10):1480-1491. PubMed doi:10.408/JCP.v68n103
14. Keck PE Jr, Calabrese JR, McQuade RD, et al; Aripiprazole Study Group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67(4):626-637. PubMed doi:10.408/JCP.v67n0414
15. Sachs G, Sanchez R, Marcus R, et al; Aripiprazole Study Group. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20(4):536-546. PubMed doi:10.17/02698106059693
16. Yatham LN, Fountoulakis KN, Rahman Z, et al. Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord. 2013;147(1-3):365-372. PubMed doi:10.1016/j.jad.2012.1.042
17. Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry. 2010;71(3):296-303. PubMed doi:10.408/JCP.09m0514yel
18. Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord. 2006;8(3):232-241. PubMed doi:10.1/j.139-5618.206.0314.x
19. Velligan DI, Weiden PJ, Sajatovic M, et al; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(suppl 4):1-46, quiz 47-48. PubMed doi:10.408/JCP.7090su1cj
20. Lage MJ, Hassan MK. The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. Ann Gen Psychiatry. 2009;8:7. PubMed doi:10.186/174-859X-8-7
21. Brissos S, Veguilla MR, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198-219. PubMed doi:10.17/2045125314540297
22. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006;67(suppl 5):15-18. PubMed
23. Gigante AD, Lafer B, Yatham LN. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs. 2012;26(5):403-420. PubMed doi:10.2165/1631310-0-0
24. Risperdal Consta [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2016.
25. Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010;68(2):156-162. PubMed doi:10.1016/j.biopsych.2010.01.015
26. Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617-624. PubMed doi:10.408/JCP.1m07530
27. Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205(2):135-144. PubMed doi:10.192/bjp.bp.13.134213
28. Ishigooka J, Nakamura J, Fujii Y, et al; ALPHA Study Group. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res. 2015;161(2-3):421-428. PubMed doi:10.1016/j.schres.2014.12.013
29. Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015;168(1-):498-504. PubMed doi:10.1016/j.schres.2015.07.07
30. International Conference on Harmonisation. E6: Good Clinical Practice: consolidated guideline. www.ich.org. Accessed July 26, 2016.
31. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435. PubMed doi:10.192/bjp.13.5.429
32. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. PubMed doi:10.192/bjp.134.4.382
33. Posner K, Brent D, Lucas C, et al. Columbia Suicide Severity Rating Scale. http://cssrs. columbia.edu/the-columbia-scale-c-ssrs/cssrsfor- research/. Accessed April 19, 2016.
34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
35. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. PubMed
36. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159-171. PubMed doi:10.1016/S0165-1781(97)0123-6
37. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;212:11-19. PubMed doi:10.1/j.160-047.1970.tb0206.x
38. Kim JH, Jung HY, Kang UG, et al. Metric characteristics of the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS): a practical combined rating scale for druginduced movement disorders. Mov Disord. 2002;17(6):1354-1359. PubMed doi:10.102/mds.1025
39. Guy W. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976:534-537.
40. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676. PubMed doi:10.192/bjp.154.5.672
41. Quiroz JA, Rusch S, Thyssen A, et al. Deltoid injections of risperidone long-acting injectable in patients with schizophrenia. Innov Clin Neurosci. 2011;8(6):20-28. PubMed
42. De Hert M, Detraux J, Peuskens J. Secondgeneration and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opin Drug Saf. 2014;13(5):605-624. PubMed doi:10.1517/1474038.2014.906579
43. Bates JA, Whitehead R, Bolge SC, et al. Correlates of medication adherence among patients with bipolar disorder: results of the Bipolar Evaluation of Satisfaction and Tolerability (BEST) study: a nationwide crosssectional survey. Prim Care Companion J Clin Psychiatry. 2010;12(5):e1-e8. PubMed doi:10.408/pc.09m083ye
44. Kishi T, Oya K, Iwata N. Long-acting injectable antipsychotics for prevention of relapse in bipolar disorder: a systematic review and metaanalyses of randomized controlled trials. Int J Neuropsychopharmacol. 2016;19(9):pyw038. PubMed doi:10.1093/ijnp/pyw038
45. Calabrese JR, Vieta E, El-Mallakh R, et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry. 2004;56(12):957-963. PubMed doi:10.1016/j.biopsych.204.09.02
46. Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manicdepressive illness: a comparison with lithium. Acta Psychiatr Scand. 1981;64(3):226-237. PubMed doi:10.1/j.160-047.1981.tb078.x
47. White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol. 1993;8(2):119-122. PubMed doi:10.1097/04850-1930820-07
48. Robinson DG, Gallego JA, John M, et al. A randomized comparison of aripiprazole and risperidone for the acute treatment of firstepisode schizophrenia and related disorders: 3-month outcomes. Schizophr Bull. 2015;41(6):1227-1236. PubMed doi:10.1093/schbul/sbv125